Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Common Stock | Award | $0 | +5.11K | +61% | $0.00 | 13.5K | Feb 27, 2024 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PFE | Stock Appreciation Rights | Award | $0 | +19.7K | $0.00 | 19.7K | Feb 27, 2024 | Common Stock | 19.7K | $26.89 | Direct | F2 | |
transaction | PFE | Stock Appreciation Rights | Award | $0 | +17.4K | $0.00 | 17.4K | Feb 27, 2024 | Common Stock | 17.4K | $26.89 | Direct | F3 |
Id | Content |
---|---|
F1 | The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. |
F2 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
F3 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |